DE602004006383D1 - Die hiv-replikation inhibierende pyrimidine und triazine - Google Patents

Die hiv-replikation inhibierende pyrimidine und triazine

Info

Publication number
DE602004006383D1
DE602004006383D1 DE602004006383T DE602004006383T DE602004006383D1 DE 602004006383 D1 DE602004006383 D1 DE 602004006383D1 DE 602004006383 T DE602004006383 T DE 602004006383T DE 602004006383 T DE602004006383 T DE 602004006383T DE 602004006383 D1 DE602004006383 D1 DE 602004006383D1
Authority
DE
Germany
Prior art keywords
triazine
hiv replication
replication inhibiting
inhibiting pyrimidines
pyrimidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004006383T
Other languages
English (en)
Other versions
DE602004006383T2 (de
Inventor
Jerome Emile Guillemont
Elisabeth Therese Pasquier
Jan Heeres
Kurt Hertogs
Eva Bettens
Paulus Joannes Lewi
Jonge Marc Rene De
Lucien Maria Koymans
Frederik Frans Daeyaert
Hendrik Maarten Vinkers
Paul Adriaan Janssen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Publication of DE602004006383D1 publication Critical patent/DE602004006383D1/de
Application granted granted Critical
Publication of DE602004006383T2 publication Critical patent/DE602004006383T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
DE602004006383T 2003-02-20 2004-02-20 Die hiv-replikation inhibierende pyrimidine und triazine Expired - Lifetime DE602004006383T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
US475012P 2003-06-02
PCT/EP2004/050177 WO2004074262A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (2)

Publication Number Publication Date
DE602004006383D1 true DE602004006383D1 (de) 2007-06-21
DE602004006383T2 DE602004006383T2 (de) 2008-01-10

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004032321T Expired - Lifetime DE602004032321D1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende indan-substituierte pyrimidine
DE602004006383T Expired - Lifetime DE602004006383T2 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende pyrimidine und triazine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602004032321T Expired - Lifetime DE602004032321D1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende indan-substituierte pyrimidine

Country Status (27)

Country Link
US (2) US7585870B2 (de)
EP (2) EP1603887B1 (de)
JP (2) JP4586013B2 (de)
KR (2) KR20050099994A (de)
CN (2) CN1751031B (de)
AP (1) AP2005003373A0 (de)
AR (2) AR044500A1 (de)
AT (2) ATE361915T1 (de)
AU (2) AU2004213186B2 (de)
BR (2) BRPI0407732A (de)
CA (2) CA2516699C (de)
CL (2) CL2004000303A1 (de)
CY (1) CY1106788T1 (de)
DE (2) DE602004032321D1 (de)
DK (1) DK1597238T3 (de)
EA (2) EA010423B1 (de)
ES (1) ES2287734T3 (de)
HR (2) HRP20050820A2 (de)
IL (2) IL169596A (de)
MX (2) MXPA05008866A (de)
MY (1) MY138308A (de)
NO (2) NO20054311L (de)
NZ (2) NZ542428A (de)
PL (2) PL226954B1 (de)
PT (1) PT1597238E (de)
TW (2) TW200500346A (de)
WO (2) WO2004074261A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
DK1951684T3 (en) 2005-11-01 2016-10-24 Targegen Inc BIARYLMETAPYRIMIDIN kinase inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2674178C (en) * 2006-12-29 2015-11-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines
AU2007341228B2 (en) * 2006-12-29 2013-04-18 Janssen Sciences Ireland Uc HIV inhibiting 5,6-substituted pyrimidines
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
NZ591366A (en) 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
EP2406253B1 (de) 2009-03-11 2013-07-03 Pfizer Inc. Als glucokinaseinhibitoren verwendete benzofuranylderivate
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2018019204A1 (zh) * 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN114072397A (zh) 2019-05-10 2022-02-18 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
JP2022531801A (ja) 2019-05-10 2022-07-11 デシフェラ・ファーマシューティカルズ,エルエルシー フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法
MX2021015628A (es) 2019-06-17 2022-04-18 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0945447A1 (de) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
WO1999050250A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
OA11674A (en) * 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
RU2312860C2 (ru) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
EP1518855B1 (de) * 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidincarbonsäureamidderivat
US7517886B2 (en) * 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
NO20054312D0 (no) 2005-09-19
AU2004213186B2 (en) 2009-10-01
EA011256B1 (ru) 2009-02-27
DK1597238T3 (da) 2007-09-10
IL169647A0 (en) 2007-07-04
TW200510339A (en) 2005-03-16
AU2004213187A1 (en) 2004-09-02
US7442705B2 (en) 2008-10-28
KR20050094896A (ko) 2005-09-28
US20060194804A1 (en) 2006-08-31
ATE506353T1 (de) 2011-05-15
CL2004000306A1 (es) 2005-04-08
CN1751030A (zh) 2006-03-22
HRP20050820A2 (en) 2006-11-30
EA200501326A1 (ru) 2006-02-24
IL169596A (en) 2017-02-28
PL226954B1 (pl) 2017-10-31
AU2004213186A1 (en) 2004-09-02
ATE361915T1 (de) 2007-06-15
KR20050099994A (ko) 2005-10-17
WO2004074261A1 (en) 2004-09-02
AU2004213187B2 (en) 2009-11-05
DE602004006383T2 (de) 2008-01-10
IL169596A0 (en) 2007-07-04
EP1603887B1 (de) 2011-04-20
CA2516699A1 (en) 2004-09-02
MXPA05008867A (es) 2005-10-05
BRPI0407741A (pt) 2006-02-14
JP2006518357A (ja) 2006-08-10
NZ542428A (en) 2007-11-30
CN100572364C (zh) 2009-12-23
ES2287734T3 (es) 2007-12-16
JP4586014B2 (ja) 2010-11-24
EP1597238A1 (de) 2005-11-23
EP1603887A1 (de) 2005-12-14
US20060142571A1 (en) 2006-06-29
BRPI0407741B8 (pt) 2021-05-25
NO20054311L (no) 2005-10-27
MY138308A (en) 2009-05-29
PL378136A1 (pl) 2006-03-06
IL169647A (en) 2013-05-30
NO20054312L (no) 2005-11-16
CA2516589A1 (en) 2004-09-02
BRPI0407741B1 (pt) 2018-05-29
PL227295B1 (pl) 2017-11-30
CA2516589C (en) 2012-04-17
HRP20050821A2 (en) 2006-11-30
PL378064A1 (pl) 2006-02-20
MXPA05008866A (es) 2005-10-05
JP4586013B2 (ja) 2010-11-24
AR044499A1 (es) 2005-09-14
BRPI0407732A (pt) 2006-02-14
TW200500346A (en) 2005-01-01
AR044500A1 (es) 2005-09-14
CY1106788T1 (el) 2012-05-23
CN1751031B (zh) 2010-07-21
PT1597238E (pt) 2007-08-08
DE602004032321D1 (de) 2011-06-01
NO20054311D0 (no) 2005-09-19
EP1597238B1 (de) 2007-05-09
JP2006518356A (ja) 2006-08-10
US7585870B2 (en) 2009-09-08
CN1751031A (zh) 2006-03-22
AP2005003373A0 (en) 2005-09-30
EA010423B1 (ru) 2008-08-29
CL2004000303A1 (es) 2005-04-08
WO2004074262A1 (en) 2004-09-02
EA200501327A1 (ru) 2006-02-24
CA2516699C (en) 2011-07-12
NZ541601A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
DE602004006383D1 (de) Die hiv-replikation inhibierende pyrimidine und triazine
EG24684A (en) HIV replication inhibiting pyrimidines
ATE500254T1 (de) Die replikation von hiv hemmende purinderivate
ATE529412T1 (de) Herbizide pyrimidine
DK1487805T3 (da) Pyrimidinderivater
DE50305279D1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
IL180963A0 (en) Hiv inhibiting bicyclic pyrimidine derivatives
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
IL180959A0 (en) Hiv inhibiting 5-heterocyclyl pyrimidines
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
ATE542802T1 (de) Hiv-inhibierende 5-substituierte pyrimidine
NO20042742L (no) Pyrimidinforbindelser
IL172848A0 (en) 2-substituted pyrimidines
IL172845A0 (en) 2-substituted pyrimidines
GB0323137D0 (en) 2,4,6- Trisubstituted pyrimidines and their different uses
ZA200506622B (en) HIV replication inhibiting pyrimidines and triazines
PT3808743T (pt) Derivados de pirimidinas inibidores do vih

Legal Events

Date Code Title Description
8364 No opposition during term of opposition